 |
AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England. They discussed Kaletra’s possible lipoatrophy advantage to Sustiva; the CDC’s new data showing a rise of HIV drug resistance in the newly infected; and HIVers dying more from non-AIDS-related cancers.
Double click for the full interview (16 minutes):
Audio recording is no longer available. Click here for the transcript.
Comments
Comments